The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2007Validation of VPS41, a protein involved in lysosomal trafficking, as a target for Parkinson disease therapy
Objective/Rationale:
Two years ago, in an MJFF-funded search for proteins that are neuroprotective in a simple worm model of PD, the most promising target to emerge was VPS41, believed to be involved... -
Target Validation, 2007Validation of Cathepsin D as a target for Parkinson’s disease therapy
Objective/Rationale:
Cathepsin D is a lysosomal protease important for clearance of long-lived proteins. Alpha-synuclein aggregation is a cardinal pathologic feature of PD. Alpha-synuclein gene... -
Rapid Response Innovation Awards, 2007Does Sporadic Parkinson's Disease Begin in the Enteric Nervous System?
Objective/Rationale:
Although the cause(s) of sporadic Parkinson's disease are still unknown, recent studies indicate the disease-related destruction is highly specific and involves a few nerve cell... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Osteopontin Gene Therapy as a Neuroprotective Treatment for Parkinson's Disease
Objective/Rationale:
Current approaches aimed at slowing or stopping the progression of Parkinson’s disease (PD) have failed due to primarily focusing on targeting specific points on the cell death...
-
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Development of MX-4565, a Novel Estrogen Analogue, for the Treatment of Parkinson's Disease
Objective/Rationale:
MX-4565 is a compound that is highly potent in protecting nerve cells from death in a number of cell culture and animal models systems. For example, it has been shown to provide... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Fisetin and Derivatives as Neuroprotective Drugs for the Treatment of Parkinson's Disease
Objective/Rationale:
Glutathione (GSH) is an antioxidant produced naturally by cells thereby providing them with a defense against oxidative stress. There is good evidence that GSH levels decrease in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.